Sutro Biopharma, Inc. (STRO) stock
STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.26+0.09 (+0.88%)
Close on Nov 11, 2026Market cap $170.12MP/E –Yield –
Sutro Biopharma profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Sutro Biopharma's profit margin for the twelve months ending Jun 30, 2026 was -395.2%. For fiscal 2025 it was -186.5%, against -366.6% the year before. The highest annual figure on record is 2.8% in fiscal 2016.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -186.5% | +180.2 |
| FY2024 | Dec 31, 2024 | -366.6% | −297.2 |
| FY2023 | Dec 31, 2023 | -69.5% | +106.4 |
| FY2022 | Dec 31, 2022 | -175.9% | −5.3 |
| FY2021 | Dec 31, 2021 | -170.6% | −95.4 |
| FY2020 | Dec 31, 2020 | -75.2% | +203.7 |
| FY2019 | Dec 31, 2019 | -278.9% | −187.0 |
| FY2018 | Dec 31, 2018 | -91.9% | −53.9 |
| FY2017 | Dec 31, 2017 | -38.1% | −40.9 |
| FY2016 | Dec 31, 2016 | 2.8% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -391.6% | −373.6 |
| Q1 FY2026 | Mar 31, 2026 | -265.0% | +171.6 |
| Q4 FY2025 | Dec 31, 2025 | -401.5% | +87.7 |
| Q3 FY2025 | Sep 30, 2025 | -586.6% | −14.0 |
| Q2 FY2025 | Jun 30, 2025 | -18.0% | +168.8 |
| Q1 FY2025 | Mar 31, 2025 | -436.6% | +10.9 |
| Q4 FY2024 | Dec 31, 2024 | -489.2% | −516.5 |
| Q3 FY2024 | Sep 30, 2024 | -572.6% | −281.4 |
| Q2 FY2024 | Jun 30, 2024 | -186.8% | +183.2 |
| Q1 FY2024 | Mar 31, 2024 | -447.5% | −52.6 |
| Q4 FY2023 | Dec 31, 2023 | 27.3% | +428.1 |
| Q3 FY2023 | Sep 30, 2023 | -291.2% | −213.7 |
| Q2 FY2023 | Jun 30, 2023 | -370.0% | −277.4 |
| Q1 FY2023 | Mar 31, 2023 | -394.9% | +268.3 |
| Q4 FY2022 | Dec 31, 2022 | -400.8% | −42.9 |
| Q3 FY2022 | Sep 30, 2022 | -77.5% | +285.3 |
| Q2 FY2022 | Jun 30, 2022 | -92.6% | −70.6 |
| Q1 FY2022 | Mar 31, 2022 | -663.2% | −456.1 |
| Q4 FY2021 | Dec 31, 2021 | -357.8% | +361.5 |
| Q3 FY2021 | Sep 30, 2021 | -362.8% | −459.0 |
| Q2 FY2021 | Jun 30, 2021 | -21.9% | −337.4 |
| Q1 FY2021 | Mar 31, 2021 | -207.1% | +66.9 |
| Q4 FY2020 | Dec 31, 2020 | -719.3% | −588.5 |
| Q3 FY2020 | Sep 30, 2020 | 96.2% | +201.3 |
| Q2 FY2020 | Jun 30, 2020 | 315.5% | +446.5 |
| Q1 FY2020 | Mar 31, 2020 | -274.0% | −108.8 |
| Q4 FY2019 | Dec 31, 2019 | -130.8% | −123.0 |
| Q3 FY2019 | Sep 30, 2019 | -105.2% | +25.5 |
| Q2 FY2019 | Jun 30, 2019 | -131.0% | +71.3 |
| Q1 FY2019 | Mar 31, 2019 | -165.1% | +42.8 |
| Q4 FY2018 | Dec 31, 2018 | -7.8% | +372.0 |
| Q3 FY2018 | Sep 30, 2018 | -130.6% | −122.5 |
| Q2 FY2018 | Jun 30, 2018 | -202.3% | −190.5 |
| Q1 FY2018 | Mar 31, 2018 | -207.9% | −200.4 |
| Q4 FY2017 | Dec 31, 2017 | -379.8% | – |
| Q3 FY2017 | Sep 30, 2017 | -8.1% | – |
| Q2 FY2017 | Jun 30, 2017 | -11.8% | – |
| Q1 FY2017 | Mar 31, 2017 | -7.5% | – |
See a number that looks wrong?